J&J Boosts Sales Forecast On Growing Demand For Cancer Drugs
Johnson & Johnson nudged its 2018 sales guidance higher Tuesday as demand for cancer drugs surged in the first quarter, even as its blockbuster Remicade continued to face competitive pressure.